Skip to main content
Michael Grossbard, MD, Oncology, New York, NY

MichaelLGrossbardMD

Oncology New York, NY

Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Director, Hematologic Malignancies Clinical Program; Laura and Isaac Perlmutter Cancer Center Professor of Medicine, NYU School of Medicine

Dr. Grossbard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Grossbard's full profile

Already have an account?

  • Office

    240 East 38th Street
    19th Floor
    New York, NY 10016
    Phone+1 646-501-9305
    Fax+1 212-731-5540

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1989 - 1992
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1986 - 1989
  • Yale School of Medicine
    Yale School of MedicineClass of 1986
  • Harvard College
    Harvard CollegeAB, Biology, Summa Cum Laude, 1982

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1999 - 2025
  • FL State Medical License
    FL State Medical License 2021 - 2023
  • MA State Medical License
    MA State Medical License 1989 - 2003
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Top Doctors: New York Metro Area Castle Connolly, 2003-2019
  • America's Top Doctors Castle Connolly, 2002-2014
  • New York Magazine: Top Doctors Castle Connolly, 2002-2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment  
    Goel A, Fan W, Patel AA, Devabahktuni M, Grossbard, ML, Clin Lymphoma, Myeloma, Leuk, 1/1/2014
  • Impact of oncology drug shortages on patient therapy: unplanned treatment changes  
    Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH, Harrison LB, Grossbard ML, J Oncol Practice, 1/1/2013
  • Phiase I study of Oxaliplatin in combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leuconvorin (G-FLIE) in patirnts with metastatic solid tumors including a...  
    Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS, J Gastrointest Cancer, 1/1/2013
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)
    Michael L. Grossbard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • KRAS mutations and outcomes for patients with stage IV NSCLC treated with frontline platinum/pemetrexed based chemotherapy.
    Levy B, Seetharamu N, Richardson S, Becker DJ, Choi W, Evans A, Bhora FY, Connery CP, Grossbard ML, Chachoua A, J Clin Oncol, 1/1/2012
  • Impact of oncology drug shortages on patient treatment.
    Becker DJ, Talwar S, Levy B, Thorn M, Roitman J, Blum RH, Harrison LB, Grossbard ML, J Clin Oncol, 1/1/2012

Lectures

  • Medical Grand Rounds: "Indolent Lymphoma: Concept to a Cure" 
    New York University - 1/1/2014
  • Grand Rounds: "Indolent Lymphoma: New Therapy Paradigms" 
    Yale Cancer Center-, New Haven, CT - 1/1/2013
  • "Frequently Asked Questions in Lymphoma" Panel Discussion 
    New York - 1/1/2013
  • Join now to see all

Other

  • Empowering targeted therapy: Lessons from Rituximab. 
    Olszewki AJ, Grossbard ML, Science STKE (Electronic Resource)
    7/13/2004
  • Malignant Lymphomas. Canada: BC Decker, Inc. (Editor) 
    Grossbard ML
    1/1/2001
  • Dose-adjusted EPOCH chemotherapy and rituximab (R-EPOCH): An effective regimen in poor pognosis aggressive B-cell non-Hodgkin's lymphoma. 
    Gutierrez ME, Grossbard M, Jaffe E, Chabner BA, Wilson WH, Monographs in Lymphoma; Physicians Education Resource
    1/1/2000
  • Join now to see all

Press Mentions

  • Perlmutter Cancer Center Appoints Inaugural Director of Center for Blood Cancers
    Perlmutter Cancer Center Appoints Inaugural Director of Center for Blood CancersJanuary 24th, 2022
  • Covid-19 and Cancer: Registry Data Suggest Cancer Tx Won’t Increase Mortality
    Covid-19 and Cancer: Registry Data Suggest Cancer Tx Won’t Increase MortalityJuly 7th, 2020
  • The Untold Toll
    The Untold TollApril 17th, 2020
  • Join now to see all

Professional Memberships